Drugs to boost cancer immunotherapy
Identifying drug synergistic with cancer immunotherapy
['FUNDING_OTHER'] · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · NIH-11177070
This project uses AI to find drugs that can help immunotherapy work better for people with advanced melanoma, bladder, kidney, or lung cancer.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR (nih funded) |
| Locations | 1 site (ALBUQUERQUE, UNITED STATES) |
| Trial ID | NIH-11177070 on ClinicalTrials.gov |
What this research studies
I use artificial intelligence to scan biological and clinical data and predict which approved or experimental drugs might act together with immunotherapy. Promising drug combinations from the AI predictions will be tested in lab models and prioritized for safety and likely patient benefit. The work brings together computational biologists, immunologists, and clinical oncologists to move top candidates toward real patient trials. If a combination looks strong, the team will push it into early-phase clinical testing at collaborating centers.
Who could benefit from this research
Good fit: Ideal candidates are people with advanced (late-stage) melanoma, bladder, kidney, or lung cancer who are receiving or eligible for immunotherapy and might enroll in clinical trials.
Not a fit: People with early-stage cancers, cancers not treated with immunotherapy, or conditions unrelated to these tumor types are unlikely to see direct benefit from this work.
Why it matters
Potential benefit: Could identify drug combinations that increase the effectiveness of immunotherapy and offer new treatment options for people with advanced cancers.
How similar studies have performed: Combining other drugs with immunotherapy has helped some patients in specific cancers, but using AI to systematically discover and prioritize new synergistic combinations is a relatively new approach.
Where this research is happening
ALBUQUERQUE, UNITED STATES
- UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR — ALBUQUERQUE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SAHU, AVINASH DAS — UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR
- Study coordinator: SAHU, AVINASH DAS
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer, Anti-Cancer Agents